208 related articles for article (PubMed ID: 27072203)
1. Sunitinib-induced thrombotic microangiopathy.
Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R
Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib-associated thrombotic microangiopathy: a significant risk.
Buckley FD; Preston G; Meiklejohn DJ; Adamson D
Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):515. PubMed ID: 24746506
[No Abstract] [Full Text] [Related]
4. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Bollée G; Patey N; Cazajous G; Robert C; Goujon JM; Fakhouri F; Bruneval P; Noël LH; Knebelmann B
Nephrol Dial Transplant; 2009 Feb; 24(2):682-5. PubMed ID: 19054798
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Park S; Lee J; Park SH; Park JO; Kang WK; Park YS; Cho JH; Lim HY
Chemotherapy; 2010; 56(6):485-91. PubMed ID: 21099221
[TBL] [Abstract][Full Text] [Related]
6. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
7. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Vigneau C; Lorcy N; Dolley-Hitze T; Jouan F; Arlot-Bonnemains Y; Laguerre B; Verhoest G; Goujon JM; Belaud-Rotureau MA; Rioux-Leclercq N
Nephrol Dial Transplant; 2014 Feb; 29(2):325-32. PubMed ID: 24302609
[TBL] [Abstract][Full Text] [Related]
8. Hypertension as a predictive factor of Sunitinib activity.
Rixe O; Billemont B; Izzedine H
Ann Oncol; 2007 Jun; 18(6):1117. PubMed ID: 17586751
[No Abstract] [Full Text] [Related]
9. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Daniels GH
Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
[No Abstract] [Full Text] [Related]
10. Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy.
Katta A; Fesler MJ; Tan A; Vuong G; Richart JM
Cancer Chemother Pharmacol; 2010 Jul; 66(2):409-12. PubMed ID: 20204363
[TBL] [Abstract][Full Text] [Related]
11. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
14. Extensive necrotizing fasciitis associated with sunitinib therapy.
Piszczek J; Dalton B; Peters T; Ruether D; Urbanski S
Clin Genitourin Cancer; 2014 Apr; 12(2):e47-9. PubMed ID: 24445249
[No Abstract] [Full Text] [Related]
15. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
[TBL] [Abstract][Full Text] [Related]
17. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
[No Abstract] [Full Text] [Related]
18. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
Eremina V; Quaggin SE
Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
